Neurocrine's CRENESSITY Gains FDA Approval For Treating Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (NBIX) said that the U.S. Food and Drug Administration has approved CRENESSITY (crinecerfont) capsules ...
Investor's Business Daily on MSN1d
Neurocrine Wins FDA Approval For Genetic Disorder Drug
Neurocrine Biosciences won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades.
US FDA approves Neurocrine Biosciences' genetic disorder drug
The U.S. Food and Drug Administration has approved Neurocrine Biosciences' drug to treat a type of genetic disorder, the ...
Daily2d
Prenatal 2D Ultrasound reveals significant adrenal gland adaptation in patients with Fetal growth restriction: Study
Fetal growth restriction (FGR) is defined as a pathological in utero growth disorder primarily caused by factors related to ...
Pharmaceutical Technology2d
Risk adjusted net present value: What is the current valuation of Pharma Mar’s Ecubectedin?
Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Sarcomas;Solid Tumor;Leiomyosarcoma;Liposarcoma;Synovial Sarcoma.